Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Riviciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 15/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 14/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 12/20 | 1.00 |
| ▸ | CCND1 | P24385 | 13/20 | 1.00 |
| ▸ | CDK2 | P24941 | 12/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 11/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 10/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 7/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 7/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 5/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 5/20 | 1.00 |
| ▸ | CCND3 | P30281 | 4/20 | 1.00 |
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | CDK7 | P50613 | 3/20 | 1.00 |
| ▸ | CCNH | P51946 | 2/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 2/20 | 1.00 |
| ▸ | MAPK15 | Q8TD08 | 2/20 | 1.00 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riviciclib SCHEMBL31702788 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL665748 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL29777523 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL290572 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL665749 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL23683025 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL17348307 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL663219 | 0.99 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL29387962 | 0.99 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL290347 | 0.99 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556375-A2 | FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | Nicholas Piramal India Limited (IN) | 2005-07-27 | — | — | EP | claimed |
| WO-2004004632-A2 | FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2004-01-15 | — | — | WO | claimed |
| EP-3491016-A1 | COMBINATION THERAPIES OF CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | Novartis AG (CH) | 2019-06-05 | — | — | EP | disclosed |
| EP-3464375-A2 | THERAPEUTIC REGIMENS FOR CHIMERIC ANTIGEN RECEPTOR (CAR)- EXPRESSING CELLS | Novartis AG (CH) | 2019-04-10 | — | — | EP | disclosed |
| EP-3393504-A1 | MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY | Novartis AG (CH) | 2018-10-31 | — | — | EP | disclosed |
| EP-3350320-A1 | CAR T CELL THERAPIES WITH ENHANCED EFFICACY | Novartis AG (CH) | 2018-07-25 | — | — | EP | disclosed |
| EP-3344996-A2 | BIOMARKERS PREDICTIVE OF CYTOKINE RELEASE SYNDROME | The Trustees Of The University Of Pennsylvania (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-3283619-A1 | METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | Barrett, David Maxwell (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2018023025-A1 | COMBINATION THERAPIES OF CHIMERIC ANTIGEN RECEPTORS ADN PD-1 INHIBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | WO | disclosed |
| WO-2017112741-A1 | MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY | NOVARTIS AG (CH) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017049166-A1 | CAR T CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017040930-A2 | BIOMARKERS PREDICTIVE OF CYTOKINE RELEASE SYNDROME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2016168595-A1 | METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | BARRETT DAVID MAXWELL (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016126608-A1 | CAR-EXPRESSING CELLS AGAINST MULTIPLE TUMOR ANTIGENS AND USES THEREOF | NOVARTIS AG (CH) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016115482-A1 | PHOSPHOGLYCERATE KINASE 1 (PGK) PROMOTERS AND METHODS OF USE FOR EXPRESSING CHIMERIC ANTIGEN RECEPTOR | NOVARTIS PHARMA AG (CH) | 2016-07-21 | — | — | WO | disclosed |
| EP-2640380-A1 | PHARMACEUTICAL COMBINATION OF PACLITAXEL AND A CDK INHIBITOR | Piramal Enterprises Limited (IN) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012069972-A1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BREAST CANCER | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012066508-A1 | PHARMACEUTICAL COMBINATION OF PACLITAXEL AND A CDK INHIBITOR | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-05-24 | — | — | WO | disclosed |
| EP-2427188-A1 | PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER | Piramal Life Sciences Limited (IN) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128443-A1 | PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-11-11 | — | — | WO | disclosed |